vimarsana.com
Home
Live Updates
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis : comparemela.com
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
These 2 randomized clinical trials compare the efficacy and safety of 2 doses of the autotaxin inhibitor ziritaxestat vs placebo in patients with idiopathic pul
Related Keywords
Helsinki ,
Eteläuomen Läi ,
Finland ,
United States ,
America ,
Los Angeles ,
Vicore Pharma ,
Devpro Biopharma ,
Astrazeneca Daiichi Sankyo ,
Redx Pharma ,
Tobym Maher ,
Shionogi Co Ltd ,
Care Center Network ,
Janssen Pharmaceuticals ,
Kinevant Sciences ,
Bristol Myers Squibb ,
Puretech Health ,
Novartis ,
Gilead Sciences ,
Pfizer ,
Boehringer Ingelheim ,
Thyron Pharmaceuticals ,
Keck School Of Medicine ,
Institute Inc ,
Source Imaging Consortium ,
National Scleroderma Foundation ,
Pulmonary Fibrosis Foundation ,
Astrazeneca ,
Genentech ,
Regeneron Pharmaceuticals ,
Glaxosmithkline ,
Daewoong Pharmaceutical Co ,
University Of Southern California ,
Group Information ,
Latin America ,
Middle East ,
North America ,
Respiratory Questionnaire ,
Eligibility Criteria ,
Secondary Outcomes ,
Pharmacodynamic Assessments ,
Baseline Characteristics ,
Annual Rate ,
Cause Mortality ,
Target Engagement ,
Keck School ,
Southern California ,
Van Den Blink ,
Interest Disclosures ,
Galecto Biotech ,
Blade Therapeutics ,
Pliant Therapeutics ,
Huitai Biomedicine ,
Open Source Imaging Consortium ,
Third Pole Therapeutics ,
Translate Bio ,
Dispersol Technologies ,
National Scleroderma ,
United Therapeutics ,
Care Center ,
Chiesi Farmaceutici Spa ,
Resolution Therapeutics ,
Nordic Biosciences ,
Pulmonary Fibrosis ,
Hoffmann La Roche ,
Horizon Therapeutics ,
Trevi Therapeutics ,
comparemela.com © 2020. All Rights Reserved.